All tests were con ducted at the p 0. 05 level of significance. Results Tables 1, 2 provide detailed information on the frequency of the multiple genotypes analyzed. 223 PTC samples were included in this study. Initially, only 50 out of 223 PTC samples were analyzed for 9 SNPs in 7 genes. Furthermore, comparing cases with the control study group the association AZD9291 cost between polymorphisms and the risk to develop thyroid cancer was initially assessed with 50 PTC samples and the SNPs that showed statistical sig nificance were selected to further confirm the finding with larger number of cases analyzed. Frequencies for CYP1A1 C4887A genotypes were 16. 7%, 71. 4%, 11. 9% and 83. 3% respectively and frequency of A allele was 48% when ini tial analysis with 50 cases was performed. Genotype CA showed 8.

7 fold, AA showed 13. 1 fold and CA AA dem onstrated 9. 2 fold higher risk, compared with wild type. On the other hand, analysis of CYP1A1 T3801C showed no statistical significance. Although GSTP1 C2293T, genotype TT accounted for 5% of PTC cases comparing with 1. 5% of controls Inhibitors,Modulators,Libraries and showed 3. 24 fold higher risk to develop thyroid cancer but did not reached to level of significance. Among 50 PTC cases, 67. 3% were homogenous for the GSTT1 null genotype compared Inhibitors,Modulators,Libraries with 25% of controls. Consequently there was 6. 24 fold increase in the risk of thyroid cancer associated with GSTT1 null genotype. No significant differences were found in the fre quency of other genes when 50 cases were compared with controls.

Using our selection Inhibitors,Modulators,Libraries criteria, in particular two genes from xenobiotic metabolizing enzyme system were chosen to elaborate the study with further 173 cases, since they have demonstrated high statistical significance and odds ratio when controls were compared to initially analyzed 50 cases form PTC sam ples. Additionally two genes, GSTM1 and NAT2 G590A, which have Inhibitors,Modulators,Libraries shown no statistical significance, were also selected for further analysis to confirm the reliability of our selection criteria. 173 further PTC cases were analyzed for these four genes and compared with control case group to assess the association between polymorphisms and the risk to develop thyroid cancer. Although the ini tial selection criteria was not deemed statistically powerful due to less number of samples nevertheless provided with the selection of genes to expand the study with statistically significant data.

As can be seen GSTM1 and NAT2 G590A genes, demonstrated no significant association with risk estimate compared to control group even when expanded with 173 more PTC Inhibitors,Modulators,Libraries samples. Among selected genes, frequencies for CYP1A1 selleck products C4887A genotypes were 47%, 44%, 9% and 53% respectively and frequency of A allele was 31%. Genotypes CA, AA and variant allele A demonstrated sig nificant differences comparing to wild type genotype CC.